Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I)LIN ZHANG; JUNHUA FAN; XIAO, Guangqing et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 18, pp 5633-5637, issn 0960-894X, 5 p.Article

Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discoveryERLANSON, Daniel A; ARNDT, Joseph W; KUMARAVEL, Gnanasambandam et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 10, pp 3078-3083, issn 0960-894X, 6 p.Article

Identification of potent and novel α4β1 antagonists using in silico screeningSINGH, Juswinder; VAN VLIJMEN, Herman; ADAMS, Steven P et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 14, pp 2988-2993, issn 0022-2623Article

The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasisGARRISON, Kendra; HAHN, Tobias; LEE, Wen-Cherng et al.Cancer immunology and immunotherapy. 2012, Vol 61, Num 4, pp 511-521, issn 0340-7004, 11 p.Article

A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resectionSUZUKI, Eiji; KIM, Samuel; LING, Leona E et al.Cancer research (Baltimore). 2007, Vol 67, Num 5, pp 2351-2359, issn 0008-5472, 9 p.Article

Intracellular TGF-β receptor blockade abrogates smad-dependent fibroblast activation in vitro and in vivoISHIDA, Wataru; MORI, Yasuji; VARGA, John et al.Journal of investigative dermatology. 2006, Vol 126, Num 8, pp 1733-1744, issn 0022-202X, 12 p.Article

Successful shape-based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)JUSWINDER SINGH; CHUAQUI, Claudio E; PAPADATOS, James L et al.Bioorganic & medicinal chemistry letters (Print). 2003, Vol 13, Num 24, pp 4355-4359, issn 0960-894X, 5 p.Article

Heat Shock Protein 90: Inhibitors in Clinical TrialsBIAMONTE, Marco A; VAN DE WATER, Ryan; ARNDT, Joseph W et al.Journal of medicinal chemistry (Print). 2010, Vol 53, Num 1, pp 3-17, issn 0022-2623, 15 p.Article

2-Aminoimidazoles inhibitors of TGF-β receptor 1BONAFOUX, Dominique; CHUAQUI, Claudio; BORIACK-SJODIN, P. Ann et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 3, pp 912-916, issn 0960-894X, 5 p.Article

An Orally Active Small Molecule TGF-β Receptor I Antagonist Inhibits the Growth of Metastatic Murine Breast CancerRAUNCH, Matthew P; HAHN, Tobias; LEE, Wen-Cherng et al.Anticancer research. 2009, Vol 29, Num 6, pp 2099-2109, issn 0250-7005, 11 p.Article

Pyrazolone based TGFβR1 kinase inhibitorsGUCKIAN, Kevin; CARTER, Mary Beth; LEE, Wen-Cherng et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 1, pp 326-329, issn 0960-894X, 4 p.Article

Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugsBIN MA; GUCKIAN, Kevin M; HAHM, Kyungmin et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 7, pp 2264-2269, issn 0960-894X, 6 p.Article

SM16, an Orally Active TGF-β Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury ModelKAI FU; CORBLEY, Michael J; CHOI, Michael et al.Arteriosclerosis, thrombosis, and vascular biology. 2008, Vol 28, Num 4, pp 665-671, issn 1079-5642, 7 p.Article